IRIS - Res&Arch Institutional Research Information System - Research & Archive

CIPRIANI, Sabrina
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.553
AS - Asia 2.029
EU - Europa 1.826
SA - Sud America 321
Continente sconosciuto - Info sul continente non disponibili 176
AF - Africa 52
OC - Oceania 4
Totale 7.961
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.384
SG - Singapore 966
IT - Italia 389
IE - Irlanda 320
CN - Cina 302
RU - Federazione Russa 255
HK - Hong Kong 246
BR - Brasile 242
VN - Vietnam 216
UA - Ucraina 159
FR - Francia 133
SE - Svezia 127
DE - Germania 97
FI - Finlandia 93
GB - Regno Unito 80
CA - Canada 69
IN - India 54
TR - Turchia 50
EE - Estonia 38
MX - Messico 30
BD - Bangladesh 28
KR - Corea 28
AR - Argentina 26
PL - Polonia 26
JP - Giappone 17
CO - Colombia 16
IQ - Iraq 16
CH - Svizzera 15
NL - Olanda 15
AT - Austria 14
ES - Italia 14
PH - Filippine 14
PK - Pakistan 14
RO - Romania 14
EC - Ecuador 13
UZ - Uzbekistan 13
ZA - Sudafrica 13
CR - Costa Rica 12
HN - Honduras 11
BE - Belgio 10
GT - Guatemala 10
CZ - Repubblica Ceca 9
ID - Indonesia 9
VE - Venezuela 9
IL - Israele 8
SA - Arabia Saudita 8
LB - Libano 7
NI - Nicaragua 7
PR - Porto Rico 7
CL - Cile 6
EG - Egitto 6
JM - Giamaica 6
KE - Kenya 6
SV - El Salvador 6
GR - Grecia 5
SC - Seychelles 5
TW - Taiwan 5
CW - ???statistics.table.value.countryCode.CW??? 4
LT - Lituania 4
NP - Nepal 4
TT - Trinidad e Tobago 4
DZ - Algeria 3
ET - Etiopia 3
KG - Kirghizistan 3
MA - Marocco 3
MY - Malesia 3
PA - Panama 3
PE - Perù 3
PY - Paraguay 3
TH - Thailandia 3
TN - Tunisia 3
AU - Australia 2
BN - Brunei Darussalam 2
GP - Guadalupe 2
HU - Ungheria 2
JO - Giordania 2
KH - Cambogia 2
NG - Nigeria 2
NO - Norvegia 2
PS - Palestinian Territory 2
SN - Senegal 2
UY - Uruguay 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AO - Angola 1
AZ - Azerbaigian 1
BB - Barbados 1
BF - Burkina Faso 1
CG - Congo 1
CI - Costa d'Avorio 1
CV - Capo Verde 1
DO - Repubblica Dominicana 1
IR - Iran 1
KZ - Kazakistan 1
LU - Lussemburgo 1
LY - Libia 1
MD - Moldavia 1
MN - Mongolia 1
NR - Nauru 1
OM - Oman 1
Totale 7.784
Salva come PNG Salva come JPEG
Città #
Singapore 722
Chandler 396
San Jose 393
Dublin 319
Ashburn 261
Hong Kong 245
San Mateo 193
Dong Ket 134
Santa Clara 131
Perugia 109
Council Bluffs 102
Boardman 101
Beijing 95
Moscow 93
Ann Arbor 90
Altamura 88
Medford 78
Princeton 78
Jacksonville 70
Lawrence 69
Lauterbourg 67
Wilmington 65
Andover 63
Los Angeles 52
New York 38
Dallas 36
Columbus 33
Izmir 32
São Paulo 32
The Dalles 30
Des Moines 27
Saint Petersburg 27
Seoul 27
Ho Chi Minh City 25
Dearborn 23
Munich 23
Helsinki 22
Orem 22
Chicago 19
North Bergen 18
Warsaw 18
Houston 17
Rome 16
Tokyo 16
Hanoi 15
London 15
Phoenix 14
Timisoara 14
Chennai 13
Frankfurt am Main 13
Naples 13
Stockholm 13
Toronto 13
Mexico City 12
San Paolo di Civitate 12
Denver 11
Montreal 11
Norwalk 11
Redmond 11
Rio de Janeiro 11
Brussels 10
Falls Church 10
Johannesburg 10
Manchester 10
Nuremberg 10
Milan 9
San José 9
Turin 9
Vienna 9
Woodbridge 9
Atlanta 8
Den Haag 8
Turku 8
Ankara 7
Baghdad 7
Boston 7
Buffalo 7
Calgary 7
Guatemala City 7
Guayaquil 7
Managua 7
Olomouc 7
Philadelphia 7
Piscataway 7
Redwood City 7
San Francisco 7
Tashkent 7
Brooklyn 6
New Delhi 6
Seattle 6
Shanghai 6
Dhaka 5
Florence 5
Nairobi 5
Ottawa 5
Paris 5
Pittsburgh 5
Queens 5
Quito 5
Ribeirão Preto 5
Totale 5.003
Salva come PNG Salva come JPEG
Nome #
The bile acid receptor GPBAR1 regulates the M1/M2 phenotype of intestinal macrophages and activation of gpbar1 rescues mice from murine colitis 162
Activation of the bile acid receptor GPBAR1 protects against gastrointestinal injury caused by non-steroidal anti-inflammatory drugs and aspirin in mice. 162
Anti-HIV Protease Inhibitors Interact With NSAIDs and Exacerbate Small Intestine Enteropathy Induced by NSAIDs 157
The bile acid receptor GPBAR1 (TGR5) is expressed in human gastric cancers and promotes epithelial-mesenchymal transition in gastric cancer cell lines 153
A Comprehensive Analysis of Small Heterodimer Partner (SHP) Target Genes in Hepatic Stellate Cells and the Discovery of a New Class of SHP Agonists That Reduces Liver Fibrosis 152
BAR502, a Dual FXR and GPBAR1 Agonist, Reverses Steatosis and Fibrosis in Rodent Model of NASH By Modulating Authophagic Genes 149
Bile acid-activated receptors in the treatment of dyslipidemia and related disorders. 148
Microencapsulated G3C hybridoma cell graft delays the onset of spontaneous diabetes in NOD mice by an expansion of Gitr+ Treg cells 148
Activation of the farnesoid-X receptor protects against gastrointestinal injury caused by non-steroidal anti-inflammatory drugs in mice. 146
BAR 501, a Novel GPBAR1 Ligand, Reverses Intestinal and Liver Inflammatory Models Demonstrating That GPBAR1 Is an Essential Modulator of Innate Immunity in Entero-Hepatic Tissues 138
Activation of FXR Improves Myocardial Fatty Acid Metabolism in a Rodent Model of Liver Steatosis 137
Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice. 129
Leflunomide protects against dyslipidemia development induced by ritonavir in mice 128
A Platelet's Guide to Synovitis 125
Bile acid activated receptors are targets for regulation of integrity of gastrointestinal mucosa 122
Development of non-antibiotic macrolide that corrects inflammation-driven immune dysfunction in models of inflammatorybowel diseases and arthritis 121
BAR501, A SELECTIVE GPBAR1 AGONIST, PROMOTES ADIPOSE TISSUE BROWNING AND AUTOPHAGY AND IMPROVES LIPID METABOLISM AND STEATO-HEPATITIS IN MICE FEED A HIGH FAT DIET 118
Glucocorticoid receptor mediates the gluconeogenic activity of the farnesoid X receptor in the fasting condition 116
Dissociation of intestinal and hepatic activities of FXR and LXRα supports metabolic effects of terminal ileum interposition in rodents. 116
Counter-regulatory role of bile acid activated receptors in immunity andinflammation. 114
BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis 114
Genetic and Pharmacological Dissection of the Role of Spleen Tyrosine Kinase (Syk) in Intestinal Inflammation and Immune Dysfunction in Inflammatory Bowel Diseases 114
BAR130, A HYODEOXYCHOLIC ACID DERIVATIVE AS THE FIRST EXAMPLE OF DUAL LXR alpha/GPBAR1 AGONIST 110
The Leukemic Isocitrate Dehydrogenase (IDH) 1/2 Mutations Impair Myeloid and Erythroid Cell Differentiation of Primary Human Hematopoietic Stem and Progenitor Cells (HSPCs) 109
The HIV Matrix Protein p17 subverts Nuclear Receptors Expression and induces a STAT1-Dependent Proinflammatory Phenotype in Monocytes 107
The nuclear receptor FXR regulates hepatic transport and metabolism of glutamine and glutamate 106
A Novel Source of Intestinal Damage: The HIV Protease Inhibitor Ritonavir Worsens Damage Caused by COX Inhibitors 105
Discovery that theonellasterol a marine sponge sterol is a highly selective FXR antagonist that protects against liver injury in cholestasis. 104
Metabolic variability of a multispecies probiotic preparation impacts on the anti-inflammatory activity 103
Maraviroc Intensification Modulates Atherosclerotic Progression in HIV-Suppressed Patients at High Cardiovascular Risk. A Randomized, Crossover Pilot Study 103
The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. 103
Ritonavir-induced lipoatrophy and dyslipidaemia is reversed by the anti-inflammatory drug leflunomide in a PPAR-γ-dependent manner. 102
Probiotics modulate intestinal expression of nuclear receptor and provide counter-regulatory signals to inflammation-driven adipose tissue activation. 102
Genetic Ablation and Pharmacological Blockade of CCR5 by the anti-HIV Small Molecule Inhibitor Maraviroc Inhibits Leukocyte Trafficking and Protects Against Mucosal Inflammation in Murine Models Colitis 102
Cystathionine gamma-lyase, a H2S-generating enzyme, is a GPBAR1-regulated gene and contributes to vasodilation caused by secondary bile acids 101
The bile acid sensor FXR protects against dyslipidemia and aortic plaques development induced by the HIV protease inhibitor ritonavir in mice. 100
The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis. 99
CCR5 Antagonism by Maraviroc Reduces the Potential for Gastric Cancer Cell Dissemination. 99
Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. 99
DISCOVERY OF BAR704, A POTENT AND SELECTIVE FXR AGONIST, THAT PROTECTS AGAINST LIVER FIBROSIS 99
Farnesoid X receptor suppresses constitutive androstane receptoractivity at the multidrug resistance protein-4 promoter. 97
FXR mediates a chromatin looping in the GR promoter thus promoting the resolution of colitis in rodents. 96
The HIV Matrix Protein p17 promotes the Activation of human hepatic stellate cells through interactions with CXCR2 and Syndecan-2 94
Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (GP-BAR1) ligands 94
Nanotraps with biomimetic surface as decoys for chemokines 94
Gpbar1 agonism promotes a Pgc-1α-dependent browning of white adipose tissue and energy expenditure and reverses diet-induced steatohepatitis in mice 93
Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA 92
Targetting farnesoid-X-receptor: from medicinal chemistry to disease treatment. 90
Impaired Itching Perception in Murine Models of Cholestasis Is Supported by Dysregulation of GPBAR1 Signaling 89
Instruction of Intestinal Microbiota by VSL#3 Reverses NASH and Accelerated Atherosclerosis Caused by Intestinal Inflammation in ApoE(-/-) Mice 87
Modulation of intestinal microbiota by the probiotic VSL#3 resets brain gene expression and ameliorates the age-related deficit in LTP. 87
SHP-dependent and -independent induction of peroxisomeproliferator-activated receptor-γ by the bile acid sensor farnesoid X receptorcounter-regulates the pro-inflammatory phenotype of liver myofibroblasts. 85
In vivo administration of ritonavir worsens intestinal damage caused by cyclooxygease inhibitors. 85
Decoding the role of the nuclear receptor SHP in regulating hepatic stellate cells and liver fibrogenesis 83
Hydrogen sulphide induces micro opioid receptor-dependent analgesia in a rodent model of visceral pain. 82
VARIABILITY IN INDUSTRIAL PRODUCTION AFFECTS PROBIOTICS ACTIVITY: IDENTIFICATION OF BATCHES OF PROBIOTIC VSL#3 THAT INCREASES INTESTINAL PERMEABILITY AND WORSENS COLITIS IN RODENTS 82
Targeting Bile Acid Receptors: Discovery of a Potent and Selective Farnesoid X Receptor Agonist as a New Lead in the Pharmacological Approach to Liver Diseases 82
GPBAR1 (TGR5) LIGATION PROTECTS AGAINST COLITIS DEVELOPMENT BY REGULATING LEUKOCYTE TRAFFINKING AND PROMOTING A IL-10 DEPENDENT SHIFT IN THE M1/M2 PHENOTYPE 80
Methotrexate improves endothelial function in early rheumatoid arthritis patients after 3 months of treatment 79
Solomonsterol A, a marine pregnane-X-receptor agonist, attenuates inflammation and immune dysfunction in a mouse model of arthritis. 79
Dietary habits and semen parameters: a systematic narrative review 78
H2S Induces Analgesia Is Mediated In Vivo Activation of mu Opioid Receptor and PI3K/AKT Pathway Activation 77
Role of Maraviroc in a dyslipidemic murine model of atherosclerosis RTV-induced 77
The HIV matrix protein p17 induces hepatic lipid accumulation via modulation of nuclear receptor transcriptoma 77
Pregnane-X-receptor mediates the anti-inflammatoryactivities of rifaximin on detoxification pathways in intestinal epithelialcells. 76
Highly specific blockade of CCR5 inhibits leukocyte trafficking and reduces mucosal inflammation in murine colitis 76
FXR Activation Reverses Insulin Resistance and Protects Against NASH Development 75
Reversal of Endothelial Dysfunction by GPBAR1 Agonism in Portal Hypertension Involves a AKT/FOXOA1 Dependent Regulation of H2S Generation and Endothelin-1 74
VSL#3 Resets Insulin Signaling and Protects against NASH and Atherosclerosis in a Model of Genetic Dyslipidemia and Intestinal Inflammation. 71
The bile acid sensor FXR is required for immune-regulatory activities of TLR-9 in intestinal inflammation 71
Preterm Birth, Low Gestational Age, Low Birth Weight, Parity, and Other Determinants of Breech Presentation: Results from a Large Retrospective Population-Based Study 69
The Bile Acid Receptor TGR5 Maintains Gastrointestinal Homeostasis and Its Activation Rescues From Gastrointestinal Injury Caused by ASA and NSAIDs 66
Essential Role of DNAX Adaptor Protein 12 (DAP12) and Spleen Tyrosine Kinase (Syk) in Inflammation-Driven Immune Dysfunction in Rodent Model of Colitis 65
Modification on ursodeoxycholic acid (UDCA) scaffold. discovery of bile acid derivatives as selective agonists of cell-surface G-protein coupled bile acid receptor 1 (GP-BAR1). 65
Reciprocal Regulation of TLRS and Nuclear Receptors: IRF-7 Dependent Regulation of FXR Mediates Counter-Regulatory Effects of TLR-9 in Colitis 64
Probiotics VSL#3 protect against development of visceral pain in murine model of irritable bowel syndrome. 61
Hyodeoxycholic acid derivatives as liver X receptor α and G-protein-coupled bile acid receptor agonists 57
Mechanistic role of p38 MAPK in gastric cancer dissemination in a rodent model peritoneal metastasis. 56
FXR Activation Corrects Immune-Dysfunction and Attenuates Inflammation in a Rodent Model of Hepatitis 54
Modification of Intestinal Microbiota by VSL#3 Protects Against Development of Pain in the Neonatal Maternal Separation Model. a Whole Genome Array Investigation 53
EXTRAMEDULLARY INVOLVEMENT IN PATIENT-DERIVED XENOGRAFT MODELS OF ACUTE MYELOID LEUKEMIA (AML) WITH NUCLEOPHOSMIN (NPM-1) MUTATION 27
Totale 7.961
Salva come PNG Salva come JPEG
Categoria #
all - tutte 37.776
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.776
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022501 0 0 0 0 31 7 14 223 8 32 85 101
2022/20231.223 81 243 7 124 115 116 0 62 431 1 32 11
2023/2024394 31 52 25 3 2 2 97 13 10 20 84 55
2024/20251.161 16 88 47 42 166 66 28 69 231 71 196 141
2025/20262.511 152 145 145 270 325 216 464 145 334 213 70 32
2026/2027839 65 64 190 459 61 0 0 0 0 0 0 0
Totale 7.961